go back

Idecabtagene Vicleucel (Abecma), up to 460 Million Cells

Rhode Island rates for HCPCS C9081

Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

How much rates vary

Facilitymedian $446,684 · 10th to 90th $446,684 to $467,735Professionalmedian $457,088 · 10th to 90th $457,088 to $457,088
$500Kfacility $446,684professional $457,088

Distribution of negotiated rates across all payers (price axis is log-scale). Each curve is scaled to its own total: facility and professional rates are different services, shown together to compare where they cluster. Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$446,683.59
Median
$446,683.59
Typical High
$467,735.14
BCBS
Setting
Professional
Modifier
Global
Typical Low
$457,088.19
Median
$457,088.19
Typical High
$457,088.19